PRESCRIBED TO MORE THAN 15,000 PATIENTS2*

The first and only approved sGC stimulator, Adempas is the only treatment for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery.1†

*Prescriptions written do not equate to prescriptions fulfilled.
Studies establishing effectiveness included predominantly patients with WHO functional class II-III.1

CTEPH=chronic thromboembolic pulmonary hypertension; PAH=pulmonary arterial hypertension; WHO=World Health Organization

ADEMPAS IS THE FIRST AND ONLY sGC STIMULATOR APPROVED BY THE FDA FOR TREATING 2 TYPES OF PULMONARY HYPERTENSION (PH) IN ADULTS1

CONSIDER ADEMPAS AS PART OF YOUR
TREATMENT ALGORITHM FOR THE FOLLOWING PATIENT TYPES1:

Lungs
PAH (WHO Group 1)
  • PAH treatment-naïve
  • PAH with ERA therapy
  • PAH with PCA therapy
Lungs
CTEPH (WHO Group 4)
  • CTEPH inoperable
  • CTEPH recurrent/persistent after surgery

Studies establishing effectiveness included predominantly patients with WHO functional class II-III.1

Review the patient profiles for PAH and CTEPH.

 

ERA=endothelin receptor antagonist; PCA=prostacyclin analog

Ask Question

Want to learn how Adempas works?

Watch the MOA video here.

MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION
References:
  1. Adempas Prescribing Information. Whippany, NJ. Bayer Pharmaceuticals Inc., 2018.

  2. Daily Metric Report. Data on file. United Biosource Corporation. Accessed March 07, 2019.

What is Adempas?